IDEAYA Biosciences, Inc.

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, VRTX has a market cap of 126.2B. Regarding current trading prices, IDYA is priced at $31.90, while VRTX trades at $480.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas VRTX's P/E ratio is 32.43. In terms of profitability, IDYA's ROE is -0.11%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IDYA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, REGN has a market cap of 81.2B. Regarding current trading prices, IDYA is priced at $31.90, while REGN trades at $770.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas REGN's P/E ratio is 18.85. In terms of profitability, IDYA's ROE is -0.11%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IDYA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check REGN's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IDYA is priced at $31.90, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IDYA's ROE is -0.11%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, IDYA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRNA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ARGX has a market cap of 47.5B. Regarding current trading prices, IDYA is priced at $31.90, while ARGX trades at $771.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ARGX's P/E ratio is 32.83. In terms of profitability, IDYA's ROE is -0.11%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, IDYA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARGX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ALNY has a market cap of 44.1B. Regarding current trading prices, IDYA is priced at $31.90, while ALNY trades at $331.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ALNY's P/E ratio is 142.82. In terms of profitability, IDYA's ROE is -0.11%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, IDYA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALNY's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IDYA is priced at $31.90, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IDYA's ROE is -0.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IDYA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SGEN's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, INSM has a market cap of 31.8B. Regarding current trading prices, IDYA is priced at $31.90, while INSM trades at $150.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas INSM's P/E ratio is -24.09. In terms of profitability, IDYA's ROE is -0.11%, compared to INSM's ROE of -1.68%. Regarding short-term risk, IDYA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check INSM's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BNTX has a market cap of 26.6B. Regarding current trading prices, IDYA is priced at $31.90, while BNTX trades at $108.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BNTX's P/E ratio is -39.60. In terms of profitability, IDYA's ROE is -0.11%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, IDYA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BNTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, IDYA is priced at $31.90, while UTHR trades at $503.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas UTHR's P/E ratio is 19.11. In terms of profitability, IDYA's ROE is -0.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IDYA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check UTHR's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MRNA has a market cap of 20.9B. Regarding current trading prices, IDYA is priced at $31.90, while MRNA trades at $51.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MRNA's P/E ratio is -7.26. In terms of profitability, IDYA's ROE is -0.11%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, IDYA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MRNA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ROIV has a market cap of 20.7B. Regarding current trading prices, IDYA is priced at $31.90, while ROIV trades at $28.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ROIV's P/E ratio is -24.74. In terms of profitability, IDYA's ROE is -0.11%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IDYA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ROIV's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IDYA is priced at $31.90, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IDYA's ROE is -0.11%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, IDYA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BGNE's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, INCY has a market cap of 20.2B. Regarding current trading prices, IDYA is priced at $31.90, while INCY trades at $100.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas INCY's P/E ratio is 15.80. In terms of profitability, IDYA's ROE is -0.11%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IDYA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check INCY's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, RPRX has a market cap of 19.8B. Regarding current trading prices, IDYA is priced at $31.90, while RPRX trades at $45.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas RPRX's P/E ratio is 25.96. In terms of profitability, IDYA's ROE is -0.11%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, IDYA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RPRX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, RVMD has a market cap of 19.7B. Regarding current trading prices, IDYA is priced at $31.90, while RVMD trades at $102.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas RVMD's P/E ratio is -19.66. In terms of profitability, IDYA's ROE is -0.11%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, IDYA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RVMD's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IDYA is priced at $31.90, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, IDYA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNA-WT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, GMAB has a market cap of 18.1B. Regarding current trading prices, IDYA is priced at $31.90, while GMAB trades at $29.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas GMAB's P/E ratio is 19.12. In terms of profitability, IDYA's ROE is -0.11%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, IDYA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check GMAB's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, IDYA is priced at $31.90, while ASND trades at $228.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ASND's P/E ratio is -52.71. In terms of profitability, IDYA's ROE is -0.11%, compared to ASND's ROE of +1.28%. Regarding short-term risk, IDYA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ASND's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, IONS has a market cap of 13.1B. Regarding current trading prices, IDYA is priced at $31.90, while IONS trades at $80.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas IONS's P/E ratio is -50.40. In terms of profitability, IDYA's ROE is -0.11%, compared to IONS's ROE of -0.69%. Regarding short-term risk, IDYA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IONS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, IDYA is priced at $31.90, while BBIO trades at $67.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BBIO's P/E ratio is -17.59. In terms of profitability, IDYA's ROE is -0.11%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, IDYA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BBIO's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IDYA is priced at $31.90, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IDYA's ROE is -0.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IDYA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KRTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, SMMT has a market cap of 12.4B. Regarding current trading prices, IDYA is priced at $31.90, while SMMT trades at $15.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas SMMT's P/E ratio is -13.27. In terms of profitability, IDYA's ROE is -0.11%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, IDYA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SMMT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BMRN has a market cap of 11.9B. Regarding current trading prices, IDYA is priced at $31.90, while BMRN trades at $61.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BMRN's P/E ratio is 22.94. In terms of profitability, IDYA's ROE is -0.11%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, IDYA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BMRN's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, IDYA is priced at $31.90, while EXEL trades at $44.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas EXEL's P/E ratio is 15.85. In terms of profitability, IDYA's ROE is -0.11%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, IDYA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check EXEL's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, JAZZ has a market cap of 11.5B. Regarding current trading prices, IDYA is priced at $31.90, while JAZZ trades at $188.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas JAZZ's P/E ratio is -32.10. In terms of profitability, IDYA's ROE is -0.11%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, IDYA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check JAZZ's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MDGL has a market cap of 9.8B. Regarding current trading prices, IDYA is priced at $31.90, while MDGL trades at $445.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MDGL's P/E ratio is -33.64. In terms of profitability, IDYA's ROE is -0.11%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, IDYA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MDGL's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, IBRX has a market cap of 9.6B. Regarding current trading prices, IDYA is priced at $31.90, while IBRX trades at $9.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas IBRX's P/E ratio is -23.85. In terms of profitability, IDYA's ROE is -0.11%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, IDYA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IBRX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IDYA is priced at $31.90, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IDYA's ROE is -0.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RXDX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, IDYA is priced at $31.90, while TECH trades at $57.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas TECH's P/E ratio is 111.32. In terms of profitability, IDYA's ROE is -0.11%, compared to TECH's ROE of +0.04%. Regarding short-term risk, IDYA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TECH's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, IDYA is priced at $31.90, while PCVX trades at $60.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas PCVX's P/E ratio is -12.73. In terms of profitability, IDYA's ROE is -0.11%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, IDYA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PCVX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ARWR has a market cap of 8.9B. Regarding current trading prices, IDYA is priced at $31.90, while ARWR trades at $63.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ARWR's P/E ratio is 39.56. In terms of profitability, IDYA's ROE is -0.11%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, IDYA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARWR's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IDYA is priced at $31.90, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IDYA's ROE is -0.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IDYA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IMGN's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IDYA is priced at $31.90, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IDYA's ROE is -0.11%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, IDYA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BPMC's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, AXSM has a market cap of 8.3B. Regarding current trading prices, IDYA is priced at $31.90, while AXSM trades at $163.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas AXSM's P/E ratio is -35.11. In terms of profitability, IDYA's ROE is -0.11%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, IDYA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AXSM's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $31.90, while HALO trades at $69.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas HALO's P/E ratio is 27.16. In terms of profitability, IDYA's ROE is -0.11%, compared to HALO's ROE of +0.93%. Regarding short-term risk, IDYA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check HALO's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $31.90, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CERE's P/E ratio is -16.47. In terms of profitability, IDYA's ROE is -0.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IDYA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CERE's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, KRYS has a market cap of 8.1B. Regarding current trading prices, IDYA is priced at $31.90, while KRYS trades at $276.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas KRYS's P/E ratio is 40.36. In terms of profitability, IDYA's ROE is -0.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IDYA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KRYS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, IDYA is priced at $31.90, while ABVX trades at $119.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ABVX's P/E ratio is -23.19. In terms of profitability, IDYA's ROE is -0.11%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, IDYA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ABVX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CYTK has a market cap of 7.6B. Regarding current trading prices, IDYA is priced at $31.90, while CYTK trades at $62.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CYTK's P/E ratio is -9.88. In terms of profitability, IDYA's ROE is -0.11%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, IDYA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CYTK's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IDYA is priced at $31.90, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IDYA's ROE is -0.11%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IDYA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MTSR's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, NUVL has a market cap of 7.4B. Regarding current trading prices, IDYA is priced at $31.90, while NUVL trades at $103.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas NUVL's P/E ratio is -19.13. In terms of profitability, IDYA's ROE is -0.11%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, IDYA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check NUVL's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, KYMR has a market cap of 7.3B. Regarding current trading prices, IDYA is priced at $31.90, while KYMR trades at $95.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas KYMR's P/E ratio is -25.37. In terms of profitability, IDYA's ROE is -0.11%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, IDYA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KYMR's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, IDYA is priced at $31.90, while PRAX trades at $340.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas PRAX's P/E ratio is -25.98. In terms of profitability, IDYA's ROE is -0.11%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, IDYA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PRAX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IDYA is priced at $31.90, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IDYA's ROE is -0.11%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IDYA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRUS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $31.90, while BLTE trades at $188.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BLTE's P/E ratio is -98.91. In terms of profitability, IDYA's ROE is -0.11%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, IDYA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BLTE's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ACLX has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $31.90, while ACLX trades at $113.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ACLX's P/E ratio is -28.96. In terms of profitability, IDYA's ROE is -0.11%, compared to ACLX's ROE of -0.73%. Regarding short-term risk, IDYA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ACLX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $31.90, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas RETA's P/E ratio is -66.29. In terms of profitability, IDYA's ROE is -0.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IDYA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RETA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, IDYA is priced at $31.90, while COGT trades at $39.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas COGT's P/E ratio is -17.99. In terms of profitability, IDYA's ROE is -0.11%, compared to COGT's ROE of -1.00%. Regarding short-term risk, IDYA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check COGT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, IDYA is priced at $31.90, while RYTM trades at $98.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas RYTM's P/E ratio is -29.91. In terms of profitability, IDYA's ROE is -0.11%, compared to RYTM's ROE of -1.84%. Regarding short-term risk, IDYA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RYTM's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, IDYA is priced at $31.90, while CRSP trades at $61.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CRSP's P/E ratio is -9.30. In terms of profitability, IDYA's ROE is -0.11%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, IDYA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CRSP's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, PTGX has a market cap of 5.8B. Regarding current trading prices, IDYA is priced at $31.90, while PTGX trades at $88.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas PTGX's P/E ratio is 139.52. In terms of profitability, IDYA's ROE is -0.11%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, IDYA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PTGX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CAI has a market cap of 5.7B. Regarding current trading prices, IDYA is priced at $31.90, while CAI trades at $19.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CAI's P/E ratio is -5.72. In terms of profitability, IDYA's ROE is -0.11%, compared to CAI's ROE of +1.97%. Regarding short-term risk, IDYA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CAI's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, IDYA is priced at $31.90, while IMVT trades at $27.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas IMVT's P/E ratio is -10.39. In terms of profitability, IDYA's ROE is -0.11%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IDYA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IMVT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IDYA is priced at $31.90, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IDYA's ROE is -0.11%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IDYA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CDTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $31.90, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IDYA's ROE is -0.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IDYA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ABCM's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $31.90, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IDYA's ROE is -0.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IDYA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ISEE's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $31.90, while PTCT trades at $68.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas PTCT's P/E ratio is 7.93. In terms of profitability, IDYA's ROE is -0.11%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, IDYA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PTCT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, IDYA is priced at $31.90, while FBIOX trades at $25.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IDYA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FBIOX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, IDYA is priced at $31.90, while CELC trades at $111.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CELC's P/E ratio is -30.36. In terms of profitability, IDYA's ROE is -0.11%, compared to CELC's ROE of -1.79%. Regarding short-term risk, IDYA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CELC's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, IDYA is priced at $31.90, while ALKS trades at $30.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ALKS's P/E ratio is 14.97. In terms of profitability, IDYA's ROE is -0.11%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, IDYA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ALKS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, TGTX has a market cap of 4.8B. Regarding current trading prices, IDYA is priced at $31.90, while TGTX trades at $30.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas TGTX's P/E ratio is 10.86. In terms of profitability, IDYA's ROE is -0.11%, compared to TGTX's ROE of +1.33%. Regarding short-term risk, IDYA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TGTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, IDYA is priced at $31.90, while MIRM trades at $92.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MIRM's P/E ratio is -109.87. In terms of profitability, IDYA's ROE is -0.11%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, IDYA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MIRM's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CGON has a market cap of 4.7B. Regarding current trading prices, IDYA is priced at $31.90, while CGON trades at $56.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CGON's P/E ratio is -28.68. In terms of profitability, IDYA's ROE is -0.11%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IDYA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CGON's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, SRRK has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.90, while SRRK trades at $44.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas SRRK's P/E ratio is -14.05. In terms of profitability, IDYA's ROE is -0.11%, compared to SRRK's ROE of -1.22%. Regarding short-term risk, IDYA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check SRRK's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.90, while FOLD trades at $14.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas FOLD's P/E ratio is -359.25. In terms of profitability, IDYA's ROE is -0.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IDYA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FOLD's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.90, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IDYA's ROE is -0.11%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AKRO's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.90, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IDYA's ROE is -0.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IDYA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALPN's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $31.90, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas OPT's P/E ratio is -1.52. In terms of profitability, IDYA's ROE is -0.11%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IDYA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check OPT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $31.90, while ERAS trades at $13.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ERAS's P/E ratio is -31.77. In terms of profitability, IDYA's ROE is -0.11%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, IDYA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ERAS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $31.90, while CRNX trades at $43.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CRNX's P/E ratio is -9.06. In terms of profitability, IDYA's ROE is -0.11%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, IDYA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CRNX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $31.90, while ACAD trades at $24.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ACAD's P/E ratio is 15.83. In terms of profitability, IDYA's ROE is -0.11%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, IDYA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ACAD's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $31.90, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IDYA's ROE is -0.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IDYA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $31.90, while NAMS trades at $34.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas NAMS's P/E ratio is -20.62. In terms of profitability, IDYA's ROE is -0.11%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, IDYA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check NAMS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, IDYA is priced at $31.90, while VKTX trades at $32.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas VKTX's P/E ratio is -10.61. In terms of profitability, IDYA's ROE is -0.11%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, IDYA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VKTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, LGND has a market cap of 3.9B. Regarding current trading prices, IDYA is priced at $31.90, while LGND trades at $196.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas LGND's P/E ratio is 87.36. In terms of profitability, IDYA's ROE is -0.11%, compared to LGND's ROE of +0.14%. Regarding short-term risk, IDYA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check LGND's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, APGE has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.90, while APGE trades at $69.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas APGE's P/E ratio is -15.99. In terms of profitability, IDYA's ROE is -0.11%, compared to APGE's ROE of -0.39%. Regarding short-term risk, IDYA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check APGE's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, TERN has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.90, while TERN trades at $40.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas TERN's P/E ratio is -41.29. In terms of profitability, IDYA's ROE is -0.11%, compared to TERN's ROE of -0.30%. Regarding short-term risk, IDYA is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TERN's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CORT has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.90, while CORT trades at $35.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CORT's P/E ratio is 43.54. In terms of profitability, IDYA's ROE is -0.11%, compared to CORT's ROE of +0.15%. Regarding short-term risk, IDYA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CORT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.90, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IDYA's ROE is -0.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IDYA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RYZB's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $31.90, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IDYA's ROE is -0.11%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IDYA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CBAY's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ADMA has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $31.90, while ADMA trades at $15.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ADMA's P/E ratio is 18.10. In terms of profitability, IDYA's ROE is -0.11%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, IDYA is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ADMA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, GPCR has a market cap of 3.6B. Regarding current trading prices, IDYA is priced at $31.90, while GPCR trades at $64.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas GPCR's P/E ratio is -17.21. In terms of profitability, IDYA's ROE is -0.11%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, IDYA is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check GPCR's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, IDYA is priced at $31.90, while CNTA trades at $26.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CNTA's P/E ratio is -14.21. In terms of profitability, IDYA's ROE is -0.11%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, IDYA is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CNTA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IDYA is priced at $31.90, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IDYA's ROE is -0.11%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, IDYA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SWTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, XENE has a market cap of 3.3B. Regarding current trading prices, IDYA is priced at $31.90, while XENE trades at $44.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas XENE's P/E ratio is -11.11. In terms of profitability, IDYA's ROE is -0.11%, compared to XENE's ROE of -0.55%. Regarding short-term risk, IDYA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check XENE's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, IDYA is priced at $31.90, while DNLI trades at $21.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas DNLI's P/E ratio is -7.25. In terms of profitability, IDYA's ROE is -0.11%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, IDYA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNLI's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ARQT has a market cap of 3.3B. Regarding current trading prices, IDYA is priced at $31.90, while ARQT trades at $28.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ARQT's P/E ratio is -79.35. In terms of profitability, IDYA's ROE is -0.11%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, IDYA is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARQT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, KNSA has a market cap of 3.3B. Regarding current trading prices, IDYA is priced at $31.90, while KNSA trades at $43.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas KNSA's P/E ratio is 96.72. In terms of profitability, IDYA's ROE is -0.11%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, IDYA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KNSA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, IDYA is priced at $31.90, while EWTX trades at $29.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas EWTX's P/E ratio is -19.39. In terms of profitability, IDYA's ROE is -0.11%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, IDYA and EWTX have similar daily volatility (3.80).Check EWTX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, TARS has a market cap of 3.2B. Regarding current trading prices, IDYA is priced at $31.90, while TARS trades at $75.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas TARS's P/E ratio is -37.95. In terms of profitability, IDYA's ROE is -0.11%, compared to TARS's ROE of -0.20%. Regarding short-term risk, IDYA is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TARS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.90, while ALMS trades at $29.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas ALMS's P/E ratio is -13.81. In terms of profitability, IDYA's ROE is -0.11%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, IDYA is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ALMS's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, VCYT has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $31.90, while VCYT trades at $38.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas VCYT's P/E ratio is 96.29. In terms of profitability, IDYA's ROE is -0.11%, compared to VCYT's ROE of +0.05%. Regarding short-term risk, IDYA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VCYT's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, BEAM has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $31.90, while BEAM trades at $28.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas BEAM's P/E ratio is -6.45. In terms of profitability, IDYA's ROE is -0.11%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, IDYA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BEAM's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $31.90, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MORF's P/E ratio is -14.88. In terms of profitability, IDYA's ROE is -0.11%, compared to MORF's ROE of -0.29%. Regarding short-term risk, IDYA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MORF's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $31.90, while VERA trades at $42.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas VERA's P/E ratio is -10.22. In terms of profitability, IDYA's ROE is -0.11%, compared to VERA's ROE of -0.60%. Regarding short-term risk, IDYA is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VERA's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $31.90, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas MOR's P/E ratio is -12.64. In terms of profitability, IDYA's ROE is -0.11%, compared to MOR's ROE of -1.84%. Regarding short-term risk, IDYA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MOR's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, CPRX has a market cap of 2.8B. Regarding current trading prices, IDYA is priced at $31.90, while CPRX trades at $24.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas CPRX's P/E ratio is 13.50. In terms of profitability, IDYA's ROE is -0.11%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IDYA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CPRX's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, NAMSW has a market cap of 2.8B. Regarding current trading prices, IDYA is priced at $31.90, while NAMSW trades at $25.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas NAMSW's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to NAMSW's ROE of -0.27%. Regarding short-term risk, IDYA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check NAMSW's competition here

IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDYA stands at 2.8B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, IDYA is priced at $31.90, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDYA currently has a P/E ratio of -25.16, whereas KDNY's P/E ratio is -12.47. In terms of profitability, IDYA's ROE is -0.11%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, IDYA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KDNY's competition here